Solid Biosciences: Leveraging Next-Generation Gene Therapy in DMD to Support a Buy-Rated Risk-Reward Profile

William Blair analyst Sami Corwin has maintained their bullish stance on SLDB stock, giving a Buy rating on January 23.

Sami Corwin’s rating is based on the view that Solid Biosciences is well positioned within the evolving treatment landscape for Duchenne muscular dystrophy (DMD), a serious and underserved disease area. By organizing a detailed discussion with the company’s CEO and a leading DMD clinician, Corwin is emphasizing the strategic importance of Solid’s focus on next-generation gene therapy as a differentiated approach in this indication.

Corwin is likely factoring in the potential of SGT-003, Solid’s advanced AAV-based gene therapy candidate, which aims to improve on earlier-generation therapies and could address key unmet needs in DMD. The engagement with both management and an external medical expert suggests confidence in the scientific rationale, clinical strategy, and long-term commercial opportunity of the program. Together, these elements support a favorable risk-reward profile for the stock, underpinning the Buy recommendation on Solid Biosciences.

Corwin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Neurogene, and Solid Biosciences. According to TipRanks, Corwin has an average return of 13.0% and a 49.62% success rate on recommended stocks.

In another report released on January 23, TipRanks – Google also upgraded the stock to a Buy with a $7.50 price target.